CJC-1295 (no DAC)

Technical Overview

CJC-1295 (no DAC), also known as Modified GRF (1-29) or Mod GRF, is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). Unlike the DAC version, it lacks the albumin-binding complex, resulting in a short duration of action that closely mimics the natural pulsatile rhythm of growth hormone release.

⏱️ Pharmacokinetics

Parameter	Value	Notes
Half-life	~30 Minutes	Rapidly degraded in plasma
Tmax	15 - 30 Minutes	Sharp peak shortly after injection
Biological Window	1.5 - 2 Hours	Effects on the pituitary are brief and pulsatile

Mechanism of Action

• GHRH Receptor Stimulation: Binds to the GHRH receptor in the anterior pituitary, triggering the acute release of endogenous growth hormone pulses [PMID: 16352683].
• Pulsatile Preservation: Because of its short half-life, it does not cause a continuous "GH bleed" or constant elevation, allowing the pituitary gland to "reset" between doses.
• Downstream IGF-1 Surge: Stimulates the liver to produce IGF-1, which provides the systemic metabolic and tissue-repair signals during the recovery window.

---

‍ Layman's Explanation

CJC-1295 (no DAC) is your body's "Precision Pulse." Imagine your body usually releases growth hormone like a rhythmic heartbeat—it comes in quick waves, then fades away. This version of the peptide follows that same rhythm. It enters your system, does its job quickly, and then leaves. This allows you to time your growth surges exactly when you need them—like right before sleep or after a hard workout—without confusing your body's internal clock.

---

️ Demographic Warnings & Precautions

️ Obesity & Metabolic State

Fasted Lipolysis Target. High visceral fat can blunt the response to GHRH. However, CJC-1295 (no DAC) is often preferred for obese individuals because its short duration allows for fasted cardio sessions without the sustained insulin-blocking effects of longer-acting versions.

Elderly (Advanced Age)

Safety & Pulsatility. Safer for the elderly than the DAC version because it mimics the natural rhythm of youth. It significantly reduces the risk of joint pain and "bloat" that elderly users often experience with constant GH elevation. Always monitor for edema in the hands and feet.

️ Heart & Cardiovascular Conditions

Lower Hypertrophy Risk. Because it does not sustain high levels of IGF-1 throughout the day, the risk of heart enlargement (LVH) is lower compared to long-acting analogs. However, any GHRH analog should be used with extreme caution in patients with active arrhythmias or structural heart disease [PMID: 38197510].

---

Upsides & Downsides

Upsides

• Mimics Natural Rhythm: Sharp pulses followed by a full pituitary reset.
• Minimal Insulin Impact: Less likely to cause long-term blood sugar issues than DAC.
• Timing Flexibility: Can be precisely timed for post-workout recovery or deep sleep cycles.

Downsides

• Frequent Injections: Often requires 1-3 doses per day for optimal results.
• Short Window: Missed doses have a much larger impact than with long-acting versions.
• WADA Status: Prohibited in all competitive sporting environments.

---

Synergies

• Ipamorelin: The "Gold Standard" stack. CJC-1295 (no DAC) provides the signal (the "nudge"), while Ipamorelin provides the surge (the "push").
• Fasted Cardio: Administering 20-30 minutes before fasted exercise maximizes the lipolytic (fat-burning) signal of growth hormone.
• Melatonin: May enhance the nighttime pulse if taken together before sleep, as GH release is highest during deep (Slow Wave) sleep.

---

Key References

• [PMID: 16352683] - Prolonged Stimulation of Growth Hormone and IGF-I by CJC-1295 (2006).
• [PMID: 38197510] - Thomas A, et al. Chromatographic analysis of growth hormone-releasing hormones in doping control (2024).
• [PMID: 41490200] - Rahman OF, et al. Therapeutic Peptides in Orthopaedics: GH secretagogues (2026).
• [PMID: 41966639] - Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies (2026).